CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain

RegulatoryPositive
AI Analysis

Summary

OKYO Pharma has cleared a key FDA milestone and is advancing toward Phase 3 trials for a neuropathic corneal pain treatment.

Clinical Trial Data

Phase

3

Outcome Details

Cleared key FDA milestone

Importance:7/10
Sentiment:
0.70
FDAregulatoryPhase 3neuropathic painophthalmology
Related Companies

Read the original article

Published by yahoo_finance on July 7, 2026 3:18 PM

Read Original